Référentiel des médicaments
Olaparib
Olaparib is a medicine in the class oncology. It is used for breast cancer.
- Classe médicamenteuse: Oncology
- Indications: breast cancer
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Code ATC
- L01XK01
- Formes courantes
- comprimé
- Interactions connues
- 102 (Majeure: 37 · Modérée: 60 · Mineure: 5)
- Noms commerciaux
- 3
- Pays et marchés
- 3
Indications
Mécanisme d'action
Olaparib inhibits PARP enzymes (PARP1, PARP2, PARP3). Cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, causing DNA damage and cancer cell death, with greater activity in cells deficient in BRCA1/2, ATM or other HRR genes.
Posologie adulte habituelle (résumé de la notice)
All indications: 300 mg orally twice daily, with or without food; swallow tablets whole, do not chew, crush, dissolve or divide
Grossesse et allaitement
- Grossesse
- Unsafe No human data. Based on its mechanism (PARP inhibition) and rat studies showing malformations and embryo loss below human exposure, it can cause fetal harm. Avoid; confirm a negative pregnancy test, and use effective contraception during treatment and for 6 months after (EU: two methods).
- Allaitement
- Unsafe No data on milk levels or infant effects. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose (US label); the EU label contraindicates breastfeeding.
Effets indésirables signalés
- Nausea
- Fatigue
- Anemia
- Vomiting
- Diarrhea
- Decreased appetite
Précautions particulières
- MDS/AML occurred in about 1.2% of patients, many fatal; monitor CBC at baseline and monthly; discontinue if confirmed.
- Pneumonitis occurred in 1.0%, including fatal cases; interrupt if suspected, discontinue if confirmed.
- Venous thromboembolism including fatal PE; VTE occurred in 8% of mCRPC patients; monitor and treat.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (102)
- Amiodarone + Olaparib Major
- Amobarbital + Olaparib Major
- Apalutamide + Olaparib Major
- Aprepitant + Olaparib Major
- Azathioprine + Olaparib Major
- Carbamazepine + Olaparib Major
- Carboplatin + Olaparib Major
- Chloramphenicol + Olaparib Major
- Cisplatin + Olaparib Major
- Clarithromycin + Olaparib Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Olaparib : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Olaparib used for?
Olaparib is a medicine in the class oncology. It is used for Breast cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer.
What side effects have been reported with Olaparib?
Nausea, Fatigue, Anemia, Vomiting, Diarrhea, Decreased appetite.
Can Olaparib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No human data. Based on its mechanism (PARP inhibition) and rat studies showing malformations and embryo loss below human exposure, it can cause fetal harm. Avoid; confirm a negative pregnancy test, and use effective contraception during treatment and for 6 months after (EU: two methods). Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose (US label); the EU label contraindicates breastfeeding.
What does Olaparib interact with?
MediHelp lists 102 known interactions for Olaparib. Major: 37 · Moderate: 60 · Minor: 5. The most serious include Amiodarone, Amobarbital, Apalutamide.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
